Tuesday, July 1, 2025 7/1/2025

Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma

Award Number: R01CA244271
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2021
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma - ABSTRACT Sleep apnea is a common and underdiagnosed syndrome that impacts at least 4% of American adults and is associated with heart disease, stroke, diabetes, and cancer mortality. In patients with sleep apnea, arterial oxygen saturation intermittently falls. Cyclic episodes are typically followed by rapid re-oxygenation. This cycle occurs as often as 60 times per hour, resulting in chronic intermittent hypoxia (CIH), a dynamic physiology that is distinct from static hypoxia. Our lab is pioneering the study of CIH’s effects on the bone marrow, immunity, and the development of hematological malignancies and we now propose the critical studies necessary to translate our work to human patients. We propose that CIH can cause resistance to chemotherapy by increasing the abundance of tumor-associated macrophages (TAMs). In this proposal, we aim: Aim 1: Test the hypothesis that severity of nighttime chronic intermittent hypoxia promotes TAMs burden Aim 2: Test the hypothesis that continuous positive airway pressure (CPAP) treatment modulates the abundance and gene expression of CD163+ CD206+ macrophages, and Aim 3: Test the hypothesis that chronic intermittent hypoxia decreases the probability of complete remission in newly diagnosed myeloma. By the end of the project period, we will have established that CIH has a clinically meaningful impact on the bone marrow, we will have performed the first deep characterization of TAMs in the context of CIH, and we will have determined the degree to which CIH severity is linked to poor response to chemotherapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $584,230 )
2025	2025	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	000	4	11/20/2024	NON-COMPETING CONTINUATION	$525,806
2025	2025	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	001	4	5/29/2025	NON-COMPETING CONTINUATION	$58,424
														Subtotal = $584,230

Issue Date FY: 2024 ( Subtotal = $555,020 )
2024	2024	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	000	3	1/15/2024	NON-COMPETING CONTINUATION	$525,806
2024	2024	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	001	3	4/17/2024	NON-COMPETING CONTINUATION	$29,214
														Subtotal = $555,020

Issue Date FY: 2023 ( Subtotal = $572,544 )
2023	2023	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	002	2	6/20/2023	NON-COMPETING CONTINUATION	$0
2023	2023	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	001	2	3/15/2023	NON-COMPETING CONTINUATION	$46,738
2023	2023	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	000	2	12/7/2022	NON-COMPETING CONTINUATION	$525,806
														Subtotal = $572,544

Issue Date FY: 2022 ( Subtotal = $584,230 )
2022	2022	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Cancer Cause and Prevention Research	000	1	11/24/2021	NEW	$584,230
														Subtotal = $584,230

Grand Total All Awards = $2,296,024

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma

Award Number: R01CA244271

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2021

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer